SS
NAMS icon

SBI Securities’s NewAmsterdam Pharma NAMS Stock Holding History

SBI Securities’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8K Buy
+615
New +$20.3K ﹤0.01% 1534
2025
Q2 		– Sell
-3
Closed -$61 – 4201
2025
Q1 		$61 Buy
+3
New +$67 ﹤0.01% 3591

Other funds holding NAMS

HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
MMC
Mizuho Markets Cayman Grand Cayman, Cayman Islands $2.67B AUM 103.47% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
SOAM
SBI Okasan Asset Management Tokyo, Japan $3.04B AUM

SBI Securities's NAMS Position: Q2 2026 in Review

SBI Securities opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 615 shares worth $20.8K. The stake represents ﹤0.01% of the portfolio and ranks #1534 among its holdings. This is a return to the name: SBI Securities previously reported a position in NAMS as recently as Q1 2025.

SBI Securities first reported a position in NAMS in Q1 2025 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • SBI Securities held 615 shares of NewAmsterdam Pharma worth $20.8K as of Q2 2026.
  • NewAmsterdam Pharma was a new SBI Securities position in Q2 2026.
  • NewAmsterdam Pharma made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1534 holding.
  • SBI Securities first reported a position in NewAmsterdam Pharma in Q1 2025 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.